Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CXA-201

- PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance

- PMLiVE

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

Manufacturers will receive a fixed yearly fee of £10m, instead of receiving individual payments per dose

- PMLiVE

Longitude Prize in final stage of deciding recipients of £8m prize

The prize will be awarded to a team of innovators who develop a point-of-care diagnostic test that will help combat antimicrobial-resistant infections

- PMLiVE

The IMC unites health industry professionals to combat antibiotic resistant infections

The coalition has formed a new call to action in addressing the way infections are managed across healthcare systems

- PMLiVE

Sandoz completes acquisition of GSK’s cephalosporin business

The acquisition confirms Sandoz’ commitment to antibiotics, following the announcement of further investment plans for European-based manufacturing network

- PMLiVE

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed

By Henry Skinner, Chief Executive Officer of the AMR Action Fund

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance

New investment adds to initial $1bn raised at the Fund's launch last year

Can Cinderella save us?

New Oxford research institute established to tackle antimicrobial resistance

Institute has received £100m in funding from Ineos

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Rethinking our approach to infectious disease preparedness

The importance of long-term strategic investment to prepare for the next threat that emerges

- PMLiVE

MSD launches antibiotic combo Recarbrio in UK

Therapeutic indicated to treat infections caused by Gram-negative bacteria

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links